Association between metabolic age and dementia risk: the role of genetic background

Abstract Background Growing evidence indicates that people with neurodegenerative diseases have altered metabolic status, but the association between metabolic age (MetAge), as assessed by circulating plasma metabolomics, and dementia remains unclear. We aimed to investigate the association between MetAge and risk of dementia and to explore whether genetic background plays a role in these associations. Method From the UK Biobank, 153,436 dementia‐free adults aged ≥55 (mean age 62.08±4.07 years; 52.54% female) at baseline were followed up to 16 years to detect incident dementia. Dementia was diagnosed based on information from patient registry following international criteria. Nuclear magnetic resonance spectroscopy was used to measure 249 metabolites from plasma samples collected at baseline. MetAge (in years) was calculated based on these metabolites using the XGBoost machine learning algorithm (25.04 to 93.11 years) and tertiled (younger 25.0‐55.7 years, middle‐aged 55.7‐62.7 years, and older 62.7‐93.1 years). AD‐related polygenic risk score (PRS AD ) was categorized as low, moderate, and high. Data were analyzed using Cox regression and Laplace regression. Result During the follow‐up (median: 14.5, interquartile range: 13.6 – 15.3 years), 4,521 (3.0%) participants developed dementia. MetAge (as continuous variable) was dose‐dependently associated with dementia risk (hazard ratio [HR] and 95% confidence interval [CI] per 5‐year increase: 1.04 [1.02, 1.06]). Compared with younger MetAge, the HR (95% CI) for dementia was 1.13 [1.03, 1.23]. Older MetAge was also associated with earlier onset [10 th percentile difference [95% CI]: ‐0.89 [‐1.27, ‐0.50] years) of dementia. In joint‐effect analysis, the HR of dementia was 2.43 (95% CI 2.08, 2.83) among participants with older MetAge and moderate‐to‐high PRS AD , compared to those with younger MetAge and low PRS AD . There was an additive interaction between older MetAge and moderate‐to‐high PRS AD on dementia (attributable proportion: 0.16 [0.01, 0.31]). Conclusion Older MetAge is associated with a moderately increased risk of dementia and accelerates dementia onset by nearly 1 year, particularly among people with a high genetic susceptibility for dementia.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-12-01
DOI
https://doi.org/10.1002/alz.088514
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association between metabolic age and dementia risk: the role of genetic background

Weili Xu, Abigail Dove, Jie Guo, Jiao Wang et al.
Alzheimer s & Dementia
Liver Disease Diagnosis and Treatment
article

Association between metabolic age and dementia risk: the role of genetic background

Weili Xu, Abigail Dove, Jie Guo, Jiao Wang, Xiangyu Ma, Yuyang Miao, Huijie Huang
article en

Abstract

Abstract Background Growing evidence indicates that people with neurodegenerative diseases have altered metabolic status, but the association between metabolic age (MetAge), as assessed by circulating plasma metabolomics, and dementia remains unclear. We aimed to investigate the association between MetAge and risk of dementia and to explore whether genetic background plays a role in these associations. Method From the UK Biobank, 153,436 dementia‐free adults aged ≥55 (mean age 62.08±4.07 years; 52.54% female) at baseline were followed up to 16 years to detect incident dementia. Dementia was diagnosed based on information from patient registry following international criteria. Nuclear magnetic resonance spectroscopy was used to measure 249 metabolites from plasma samples collected at baseline. MetAge (in years) was calculated based on these metabolites using the XGBoost machine learning algorithm (25.04 to 93.11 years) and tertiled (younger 25.0‐55.7 years, middle‐aged 55.7‐62.7 years, and older 62.7‐93.1 years). AD‐related polygenic risk score (PRS AD ) was categorized as low, moderate, and high. Data were analyzed using Cox regression and Laplace regression. Result During the follow‐up (median: 14.5, interquartile range: 13.6 – 15.3 years), 4,521 (3.0%) participants developed dementia. MetAge (as continuous variable) was dose‐dependently associated with dementia risk (hazard ratio [HR] and 95% confidence interval [CI] per 5‐year increase: 1.04 [1.02, 1.06]). Compared with younger MetAge, the HR (95% CI) for dementia was 1.13 [1.03, 1.23]. Older MetAge was also associated with earlier onset [10 th percentile difference [95% CI]: ‐0.89 [‐1.27, ‐0.50] years) of dementia. In joint‐effect analysis, the HR of dementia was 2.43 (95% CI 2.08, 2.83) among participants with older MetAge and moderate‐to‐high PRS AD , compared to those with younger MetAge and low PRS AD . There was an additive interaction between older MetAge and moderate‐to‐high PRS AD on dementia (attributable proportion: 0.16 [0.01, 0.31]). Conclusion Older MetAge is associated with a moderately increased risk of dementia and accelerates dementia onset by nearly 1 year, particularly among people with a high genetic susceptibility for dementia.

Alzheimer s & DementiaVol. 20(S2)
Army Medical University (CN), Tianjin Medical University General Hospital (CN), Karolinska Institutet (SE), China Agricultural University (CN), Tianjin Medical University (CN)
Openalex Percentile: Top 63%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.